| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Milestone Scientific, Inc.$0.35
+0.01 (+2.82%)
F 2Pipeline Score MedTech · Commercial
Market Cap
33.73 M
EPS
-0.06
P/E Ratio
-
Value Trade
26.91 K
SEC Financials
Q1 2026Dilution Risk
Revenue
2.16 M
Operating CF
86.84 K
Total Assets
7.96 M
Total Liabilities
5.68 M
Equity
2.28 M
D/E Ratio
12,345
14.33 %
Week
24.72 %
1 Month
45.41 %
3 Month
27.67 %
6 Month
-81.76 %
5 Year
-97.31 %
All Time
Cash Data
Cash Position
1.20 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
16.34 K
52 Week Range
0.22 - 1.01
% held by Insiders
15.72 %
% held by Institutions
5.11 %
Enterprise Value
33.52 M
Total Shares
80.44 M
Short %
0.71 %
Float Shares
66.61 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 870 of 905)
Percentile RankMilestone Scientific, Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MLSS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MLSS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MLSS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MLSS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MLSS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MLSS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MLSSMilestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025
Milestone Scientific reported a modest revenue increase for Q4 2025 and a 4% rise for the full year, driven by international sales. The company anticipates significant growth in 2026, particularly with CompuFlo sales expected to rise by 400%. New leadership has focused on financial discipline and strategic investments to enhance growth prospects.
Read more →MLSSMilestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference Call
Milestone Scientific Inc. has scheduled a conference call for April 1, 2026, to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The call will also cover corporate progress and developments. Interested parties can join via telephone or access a webcast of the call.
Read more →MLSSMilestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
Milestone Scientific has launched the CompuFlo® Advisor Program aimed at boosting commercial adoption and generating clinical data for Medicare reimbursement. Targeting high-volume interventional pain and anesthesia practices, the program will initially focus on select MAC jurisdictions. The initiative includes engaging Key Opinion Leaders and plans for national expansion to enhance revenue visibility.
Read more →MLSSMilestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership
Milestone Scientific Inc. has reported operational progress and growth initiatives under new CEO Eric Hines. The company has reduced operating expenses by 20% while achieving modest revenue growth. Hines has outlined strategies to enhance sales and marketing efforts, particularly in the dental and medical segments, and is optimistic about the company's future performance.
Read more →MLSSMilestone Scientific Commits to Regaining NYSE American Compliance Following Notification
Milestone Scientific Inc. has received a notification from NYSE American regarding non-compliance with listing standards due to insufficient stockholders' equity. The company reported approximately $3.3 million in equity and has experienced losses over the past five years. Milestone plans to submit a compliance plan by November 7, 2025, to address these issues and aims to regain compliance by April 8, 2027.
Read more →MLSSMilestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management
Milestone Scientific has appointed Dr. Dawood Sayed to its Board of Directors to enhance its commercial and clinical strategies in pain management. Dr. Sayed, a prominent figure in interventional pain medicine, brings extensive experience and leadership in advancing innovative pain therapies. His appointment is expected to accelerate the adoption of Milestone's CompuFlo® Epidural System, which offers a safer alternative for spinal procedures.
Read more →MLSSMilestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025
Milestone Scientific reported a 25% revenue increase to $2.3 million for Q2 2025, driven by strong international dental sales. The company appointed Eric Hines as CEO and Jason Papes as Senior VP of Sales and Marketing to enhance leadership. Despite revenue growth, Milestone faced operating and net losses, indicating challenges ahead.
Read more →MLSSMilestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call
Milestone Scientific Inc. has scheduled a conference call for August 15, 2025, to discuss its financial results for Q2 2025 and corporate developments. The call will be accessible via telephone and webcast, allowing stakeholders to gain insights into the company's progress. An audio replay will be available until August 29, 2025.
Read more →MLSSMilestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing
Milestone Scientific has appointed Jason Papes as Senior Vice President, Global Head of Sales and Marketing. Papes brings over 30 years of experience in healthcare sales and marketing, having previously led successful initiatives in various medical technology firms. His role will be crucial in advancing the commercial rollout of the CompuFlo Epidural System and enhancing the STA Single Tooth Anesthesia System's adoption.
Read more →MLSSMilestone Scientific Appoints Eric C. Hines as Chief Executive Officer
Milestone Scientific has appointed Eric C. Hines as its new CEO, effective immediately. Hines brings over 25 years of leadership experience, particularly in scaling sales-driven companies. His appointment comes at a crucial time as the company aims to accelerate the adoption of its CompuFlo technology and expand into new markets. Recent reimbursement progress is seen as a strong foundation for future growth.
Read more →MLSSMilestone Scientific Commences Sales of CompuFlo® Epidural System at The Painless Center in Tenafly, New Jersey
Milestone Scientific has begun commercial sales of its CompuFlo Epidural System at The Painless Center in Tenafly, New Jersey. Led by Dr. Chi-Shin Jason Chiu, the center aims to enhance patient safety and comfort through advanced technologies. The CompuFlo system utilizes proprietary technology to improve the accuracy of epidural injections, reflecting Milestone's commitment to innovation in pain management.
Read more →MLSSMilestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors
Milestone Scientific has appointed Shanth Thiyagalingam to its Board of Directors, effective May 14, 2025. Thiyagalingam brings over 20 years of experience in the medical device and pharmaceutical sectors, focusing on commercial scaling and product innovation. His leadership is expected to support the company's strategy for expanding the adoption of its CompuFlo® Epidural System and enhancing commercial initiatives.
Read more →MLSSMilestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2025
Milestone Scientific reported a revenue of $2.2 million for Q1 2025, reflecting a slight decrease from the previous year. The company noted positive developments in its medical segment, particularly with the CompuFlo® Epidural System, which is gaining traction among new practices. Despite an increase in operating losses, Milestone secured convertible financing to support its growth initiatives and is optimistic about expanding its market presence.
Read more →Competitive Position
How MLSS ranks across every disease it competes inCompetitive Position is a premium feature
See how MLSS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial